Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TU9W
|
|||
| Drug Name |
BIIB054
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 2 | [1] | |
| Company |
Biogen Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Synuclein alpha (SNCA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Alzheimer's disease | |||
| Parkinson's disease | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Parkinson disease | |||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Amyloid formation | |||
| WikiPathways | Ectoderm Differentiation | |||
| Parkinsons Disease Pathway | ||||
| Parkin-Ubiquitin Proteasomal System pathway | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.